Pharmaceutical Technology

JUNE 16, 2025

Find out more According to GlobalData’s Acute Lymphocytic Leukemia: Epidemiology Forecast to 2029 report, the number of diagnosed incident cases in the eight major markets (8MM: China, France, Germany, Italy, Japan, Spain, the UK and the US) is projected to increase from 25,636 in 2025 to 26,482 by 2029 at an annual growth rate of 1.16%.

Labelling

European Pharmaceutical Review

AUGUST 30, 2022

It has highlighted the value of cutting-edge technologies, such as messenger RNA (mRNA) vaccines, and reinforced the industry’s understanding of the power of collaboration, including with contract partners such as contract development and manufacturing organisations (CDMOs). The rise of the nasal vaccine route.

Vaccines

European Pharmaceutical Review

MAY 10, 2024

The US Food and Drug Administration (FDA) has granted the first approval of an Epstein–Barr virus-related mRNA therapeutic cancer vaccine. WGc-043 demonstrated “superior safety and efficacy compared to other publicly available mRNA therapeutic cancer vaccines”, WestGene explained. billion by 2029.

Vaccines

Express Pharma

AUGUST 31, 2023

The global market for mRNA-based oncology therapies is expected to reach a record-breaking $2 billion by 2029. per cent share by 2029, according to GlobalData. If successful, this trial will mark the first time an mRNA cancer vaccine and an immune checkpoint inhibitor have shown improved recurrence-free survival rates.

Immunization

European Pharmaceutical Review

MAY 7, 2024

percent compound annual growth rate (CAGR) between 2024 to 2029. billion by 2029. Injectable vaccines activate the immune system to help to prevent infectious conditions such as influenza. by 2029 appeared first on European Pharmaceutical Review. The market is anticipated to value $1139.4 Eli Lilly and Company and Sandoz.

Vaccines

European Pharmaceutical Review

SEPTEMBER 1, 2023

The global mRNA-based oncology therapy market is expected to reach $2 billion by 2029, according to GlobalData. percent share by 2029, the research has shown. If successful, this trial will mark the first time an mRNA cancer vaccine and an immune checkpoint inhibitor have shown improved recurrence-free survival rates.

Immunization

Express Pharma

NOVEMBER 3, 2023

Pfizer has recently announced the FDA approval of Penbraya, the first and only pentavalent vaccine for coverage against the most common serogroups causing meningococcal disease in people aged 10 to 25 years. Penbraya has the potential to help simplify complex vaccination schedules by providing broader serogroup coverage with fewer doses.”

Vaccines

European Pharmaceutical Review

AUGUST 21, 2023

Part of this growth was driven by Arexvy, which in May 2023, became the world’s first approved RSV vaccine for older adults. billion sales globally by 2029, this could offset Keytruda’s decline sales expected after its loss of exclusivity in 2028, GlobalData highlighted. percent market capitalisation growth due to its $10.8

Biosimilars

European Pharmaceutical Review

JUNE 16, 2023

According to Maximize Market Research , new technologies are expected to boost the clinical trials market between 2022 to 2029, especially as the industry and patients are shifting towards digitalisation approaches and personalised medicines.

Communication

pharmaphorum

AUGUST 31, 2022

from 2021 to 2029. It seems the FDA is trying to get ahead of any scepticism about gene therapies that proved complicated when encouraging uptake of COVID-19 vaccines. FDA backing. Earlier this year, bluebird bio received the support of the FDA’s advisory committee for approval in a vote, which emerged 15 to 0 in favour of approval.

Compounding

Pharmaceutical Technology

SEPTEMBER 23, 2022

It is expected to expire on 21 January 2029, with paediatric exclusivity lasting until 21 July 2029. In June, the company received approval from the FDA for a pneumococcal 15-valent conjugate vaccine , Vaxneuvance, for children aged between six weeks and 17 years.

Vaccines

FDA Law Blog: Biosimilars

DECEMBER 3, 2023

covered insulin product or vaccine). Each phase-in policy allows eligible manufacturers to build up in a stepwise manner to the 10% and 20% applicable discounts by 2029 and 2031, respectively. state pharmaceutical assistance programs). had Part D expenditures on or before August 16, 2022).

Labelling

Pharmaceutical Technology

JULY 8, 2025

How will RFK Jr’s American dream for vaccines play out? By GlobalData Learn more about Strategic Intelligence “Efimosfermin is a key growth opportunity for GSK with multiple development options and potential first launch in 2029. Stay proactive with real-time data and expert analysis.

Packaging

pharmaphorum

SEPTEMBER 30, 2022

8,414,921), which covers the co-formulation of sitagliptin and metformin and is due to expire in 2029. The two judgments are a big victory for Merck, given that Januvia remains its third best-selling product after cancer immunotherapy Keytruda (pembrolizumab) and HPV vaccine Gardasil, with sales of almost $2.5

Diabetes

Viseven

JANUARY 15, 2025

in 2029 , with a compound annual growth rate of 27.9%. Artificial intelligence can assist governments and healthcare institutions in combating pandemics , including monitoring and predicting outbreaks, speeding up diagnostics and research, repurposing existing drugs, and even accelerating vaccine design and development.

Pharmaceutical Companies

Pharmaceutical Technology

MAY 16, 2023

million by 2029. on 31 March 2023, owing to the discontinuation of their respiratory syncytial virus (RSV) vaccine at Phase III development and ongoing concerns over lawsuits around the company’s baby powder products. Sanofi and Regeneron’s market capitalisation grew by 12.4%

Diabetes

Pharmaceutical Technology

OCTOBER 24, 2024

Conflict in Gaza, Sudan and Yemen have complicated polio vaccination efforts, and the GPEI now expects eradication to take until 2029.

Vaccines